{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:31:04Z","timestamp":1781109064207,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,21]]},"DOI":"10.7759\/cureus.82701","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:12:36Z","timestamp":1745248356000},"source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-Induced Hypophysitis: A Rare Immune-Related Adverse Event in a Patient With Metastatic Non-small Cell Lung Cancer"],"prefix":"10.7759","author":[{"given":"Ammar","family":"Al Heyasat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maida S","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murad","family":"Alkharabsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Bani Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Poojary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje AT","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, et al.. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018, 124:3706-14. 10.1002\/cncr.31629","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright JJ","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021, 17:389-99. 10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13033","article-title":"Post-gastric bypass hypoglycaemia: a review","volume":"85","author":"Shantavasinkul PC","year":"2016","unstructured":"Shantavasinkul PC, Torquati A, Corsino L. Post-gastric bypass hypoglycaemia: a review. Clin Endocrinol (Oxf). 2016, 85:3-9. 10.1111\/cen.13033","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-024-00332-2","article-title":"Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report","volume":"10","author":"Fujimiya T","year":"2024","unstructured":"Fujimiya T, Azuma K, Togashi Y, Kuwata K, Unezaki S, Takeuchi H. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. J Pharm Health Care Sci. 2024, 10:10. 10.1186\/s40780-024-00332-2","journal-title":"J Pharm Health Care Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31244","article-title":"Primary hyperparathyroidism: is image localization alone sufficient to ensure long-term cure in unifocal disease?","volume":"14","author":"Mathew J","year":"2022","unstructured":"Mathew J, Arjunan R, Althaf S, Halkud R. Primary hyperparathyroidism: is image localization alone sufficient to ensure long-term cure in unifocal disease?. Cureus. 2022, 14:e31244. 10.7759\/cureus.31244","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun DJ","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017, 13:195-207. 10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama S","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, et al.. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014, 6:230-45.","journal-title":"Sci Transl Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonzalez-Rodriguez E","year":"2016","unstructured":"Gonzalez-Rodriguez E, Rodr\u00edguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016, 21:804-16. 10.1634\/theoncologist.2015-0509","journal-title":"Oncologist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001129","article-title":"Hypophysitis secondary to pembrolizumab: a case report and review of the literature","volume":"33","author":"Montero P\u00e9rez O","year":"2022","unstructured":"Montero P\u00e9rez O, S\u00e1nchez Escudero L, Guzm\u00e1n Ramos MI, Avi\u00f1\u00f3 Tarazona V. Hypophysitis secondary to pembrolizumab: a case report and review of the literature. Anticancer Drugs. 2022, 33:94-9. 10.1097\/CAD.0000000000001129","journal-title":"Anticancer Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad135","article-title":"Nothing great comes without its risks: a rare case of pembrolizumab-induced hypophysitis","volume":"2","author":"Fernando A","year":"2023","unstructured":"Fernando A, Mittal A, Cheema R. Nothing great comes without its risks: a rare case of pembrolizumab-induced hypophysitis. JCEM Case Rep. 2023, 2:luad135. 10.1210\/jcemcr\/luad135","journal-title":"JCEM Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/348789-pembrolizumab-induced-hypophysitis-a-rare-immune-related-adverse-event-in-a-patient-with-metastatic-non-small-cell-lung-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T15:12:37Z","timestamp":1745248357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/348789-pembrolizumab-induced-hypophysitis-a-rare-immune-related-adverse-event-in-a-patient-with-metastatic-non-small-cell-lung-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.82701","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,21]]}}}